Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc ...

UNITY Biotechnology (UBX) announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.